We are thrilled to announce that we will be attending Immuno-Oncology (IO) 360° in Boston, MA. This premier summit will host over 600 attendees from across pharma, biotech, and research, covering the current trends and developments in IO. Come check out our booth #18, to grab some swag and meet our team. We look forward to sharing how Biocycogen’s innovative platforms and integrated services can help advance your research.
What is Immuno-Oncology 360°?
Immuno-Oncology (IO) 360° serves as an annual gathering for all stakeholders, from science and business communities, to discuss the latest progress in cancer treatments. This year’s future-focused agenda will include multi-dimensional talks on translational science, operational strategies, clinical development, and more. This is a great opportunity to form meaningful connections and collaborate with biopharma leaders, investors and policymakers to accelerate the development of therapeutics for cancer.
Event Overview
Date: February 10th - 12th, 2026
Venue: Sheraton Boston Hotel, 39 Dalton St, Boston, MA 02199
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
See you in Boston!
